RecallRadar

FDA Drug recall D-0984-2022

Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-9…

On 2022-06-15 the FDA classified a Class III recall of Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-9… by Novartis Pharmaceuticals, citing failed Impurities/Degradation Specifications.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0984-2022
ClassificationClass III
Statusterminated
Initiated2022-05-10
Published2022-06-15
Last updated2026-09-13 11:52 UTC
CompanyNovartis Pharmaceuticals
DistributionUS

Product

Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-95) and b) 4 pouches x 5 single-use containers (NDC 0078-0911-94), Rx Only, Manufactured by: The Ritedose Corporation Columbia, SC 29203; Distributed by: Novartis Pharmaceuticals Corporation East Hanover, NJ 07936.

Reason

Failed Impurities/Degradation Specifications.

Identifiers

ndc0078-0911-05
ndc0078-0911-12
ndc0078-0911-95
ndc0078-0911-94
code_infoLot #: a) and b) 20DJ3, Exp. Date 03/2023.

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0984-2022%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.